Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study
Dritte-Generation-EGFR-TKIs kombiniert mit Chemotherapie bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: Real-World-Studie
Cancer Science · 2026-02 · 117 (2) · 476-490
DOI: 10.1111/cas.70269 ↗Auf einen Blick
Bei 382 Patient:innen mit fortgeschrittenem EGFR-mutiertem NSCLC waren Drittgeneration-EGFR-TKIs plus Chemotherapie mit median 30,9 Monaten PFS und 53,9 Monaten OS verbunden. Die ORR lag bei 76,4 %.
Fragestellung
Wie wirksam, sicher und mit welchem Progressionsmuster sind Drittgeneration-EGFR-TKIs plus Chemotherapie bei fortgeschrittenem EGFR-mutiertem NSCLC im Versorgungsalltag?
Methode
Retrospektive, monozentrische Beobachtungsstudie im Real-World-Setting; 382 Patient:innen mit Erstlinientherapie aus Juli 2016 bis Mai 2024.
Ergebnisse
Medianes Follow-up 34,6 Monate (95 %-KI 32,2–35,6), medianes PFS 30,9 Monate (95 %-KI 27,5–39,3), medianes OS 53,9 Monate (95 %-KI 46,2–NR). ORR 76,4 %, DCR 98,2 %, 35,9 % mit Grad-3-oder-höheren AEs. Zwischen den TKI-Gruppen kein signifikanter PFS-Unterschied (HR 0,75; 95 %-KI 0,51–1,10).
Schlussfolgerung der Autor:innen
Die Erstlinienkombination aus Drittgeneration-EGFR-TKI und pemetrexedbasierter Chemotherapie zeigte bei fortgeschrittenem EGFR-mutiertem NSCLC eine günstige ORR und einen PFS-Vorteil.
Kernaussagen
- 382 Patient:innen in einer retrospektiven Real-World-Studie
- Medianes PFS 30,9 Monate; medianes OS 53,9 Monate
- Keine signifikanten Unterschiede zwischen den TKI-Gruppen beim PFS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Science, online erschienen am 28.11.2025. Verfasst von YuQin Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital With Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Important Talents of Jiangsu Province, National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
FLAURA2 has demonstrated that third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) plus chemotherapy brought a significant survival benefit over EGFR‐TKI monotherapy. This suggests that EGFR‐TKIs combined with chemotherapy may be a viable therapeutic strategy. Our study aimed to evaluate the efficacy, safety, and progression pattern of third‐generation EGFR‐TKIs combined with chemotherapy in advanced EGFR ‐mutant ( EGFR m) non‐small cell lung cancer (NSCLC) in the real world. This study designed as an observational, retrospective, single‐center, real‐world project enrolled 382 NSCLC individuals receiving third‐generation EGFR‐TKIs combined with platinum‐based chemotherapy as first‐line therapy. The primary end point was progression‐free survival (PFS), and secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). From July 2016 to May 2024, 382 patients were retrospectively included for the analysis. Of these patients, 120, 165, and 97 patients received osimertinib, aumolertinib, and furmonertinib plus chemotherapy as first‐line therapy, respectively. Overall, the median follow‐up duration was 34.6 months (95% CI: 32.2–35.6), the median PFS was 30.9 months (95% CI: 27.5–39.3), and the median OS was 53.9 months (95% CI: 46.2–NR). Overall, the ORR was 76.4% and the DCR was 98.2%. One hundred thirty‐seven (35.9%) individuals experienced Grade 3 or higher AEs. Different third‐generation EGFR‐TKI groups show no statistically significant difference in PFS (HR = 0.75; 95% CI: 0.51–1.10; p = 0.25) after inverse probability of treatment weighting (IPTW), nor in AEs or severe AEs ( p = 0.852; p = 0.502). First‐line third‐generation EGFR‐TKI combined with pemetrexed‐based chemotherapy demonstrated a favorable ORR and PFS benefit in advanced EGFR m NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
- Department of Oncology, Jiangyin Clinical College of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Qi Liang, Renhua Guo
Förderung
- Medical Important Talents of Jiangsu Province
- National Natural Science Foundation of China
- Graduate Research and Innovation Projects of Jiangsu Province
- Cancer Foundation of China
Zitieren
APA
Jiang, Y., Liang, Q., Zhu, Y., Liang, X., Huang, R., Zhou, W., Zhang, C., Li, J., Xu, J., & Guo, R. (2026). Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study. Cancer Science, 117(2), 476-490. https://doi.org/10.1111/cas.70269
Vancouver
Jiang Y, Liang Q, Zhu Y, Liang X, Huang R, Zhou W, et al. Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study. Cancer Science. 2026;117(2):476-490. doi:10.1111/cas.70269
BibTeX
@article{Jiang2026,
author = {Jiang, YuQin and Liang, Qi and Zhu, Yuting and Liang, Xiao and Huang, Ruohan and Zhou, Wenxin and Zhang, Chen and Li, Jun and Xu, Jiali and Guo, Renhua},
title = {Third‐Generation EGFR ‐ TKIs Combined With Chemotherapy in Advanced Non‐Small Cell Lung Cancer: A Real‐World Study},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {2},
pages = {476--490},
doi = {10.1111/cas.70269}
}
EUVIMED